Modality
Bispecific Ab
MOA
CFTRmod
Target
MALT1
Pathway
Cell Cycle
WMASPsoriasis
Development Pipeline
Preclinical
~May 2014
→ ~Aug 2015
Phase 1
~Nov 2015
→ ~Feb 2017
Phase 2
~May 2017
→ ~Aug 2018
Phase 3
Nov 2018
→ Nov 2025
Phase 3Current
NCT06973003
328 pts·WM
2023-07→2025-11·Terminated
NCT03357238
743 pts·Psoriasis
2018-11→TBD·Not yet recruiting
1,071 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-11-045mo agoPh3 Readout· WM
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
P3
Not yet…
P3
Termina…
Catalysts
Ph3 Readout
2025-11-04 · 5mo ago
WM
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06973003 | Phase 3 | WM | Terminated | 328 | UPDRS |
| NCT03357238 | Phase 3 | Psoriasis | Not yet recr... | 743 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| Darafutibatinib | BioNTech | Preclinical | PRMT5 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Cevisacituzumab | Alnylam | Preclinical | MALT1 |